XXXX and anti-inflammatory therapy in chronic @entity1069 .

@entity1 @entity32 @entity1069 @entity26 @entity2371 @entity158 @entity2723 @entity13624
Anti-inflammatory medications have been used for the treatment of chronic @entity1069 /chronic @entity2371 ( @entity2723 /CPPS), given that @entity32 and @entity158 are traditionally associated with this condition. The National Institutes of Health (NIH) classification divides category III into (1) category IIIA-- @entity1 with white blood cells (WBCs) in their expressed prostatic secretions, post-prostate massage urine (voided bladder urine-3 [VB3]) or semen; and (2) category IIIB--those without WBCs. However, recent studies indicate that the ability of WBC count alone to distinguish @entity1 with symptoms from those without appears limited. Other markers of @entity32 , such as cytokines, may correlate better with clinical findings. The mechanisms of @entity32 continue to be investigated, including contributions from reactive @entity26 species, autoimmune response, @entity13624 , and even endocrine dysfunction. There have been few controlled studies of anti-inflammatory therapy for chronic @entity1069 . In the only randomized double-blind placebo-controlled trial, the NIH-Chronic @entity1069 Symptom Index (CPSI) total, domain, and @entity158 scores significantly decreased from baseline in all groups, but the difference was not statistically significant. Other medications that have some theoretic anti-inflammatory properties have shown promising early results. Further study of currently available anti-inflammatory medications may be warranted, especially in longer trials, which may allow resolution of the significant placebo effect commonly seen in the short term in @entity1 with CPPS. Further discussion is needed to either validate, modify, or abolish the distinction between category IIIA and IIIB in the NIH classification.
